Orchestra BioMed announces appointment of Cleary to board of directors

Orchestra BioMed (OBIO) announced the appointment of Christopher Cleary to its Board of Directors as an independent member, effective as of January 30, 2025. Cleary brings over three decades of experience in corporate development, mergers, acquisitions, strategic investments and structured R&D collaborations, having significantly impacted the medical technology industry through his strategic leadership and visionary approach. After seven years of dedicated service on Orchestra BioMed’s Board of Directors, Eric Rose, M.D. will transition to Board Member Emeritus and Strategic Advisor to Orchestra BioMed.